Exploratory Evaluation of EGFR-Targeted Anti-Tumor Drugs for Lung Cancer Based on Lung-on-a-Chip

被引:19
|
作者
Tan, Jianfeng [1 ,2 ]
Sun, Xindi [3 ]
Zhang, Jianhua [1 ]
Li, Huili [4 ]
Kuang, Jun [1 ]
Xu, Lulu
Gao, Xinghua [3 ]
Zhou, Chengbin [2 ,4 ]
机构
[1] Southern Med Univ, Dept Thorac Surg, Shenzhen Hosp, Shenzhen 518101, Peoples R China
[2] Southern Med Univ, Sch Clin Med 2, Guangzhou 510030, Peoples R China
[3] Shanghai Univ, Mat Genome Inst, Shanghai 200444, Peoples R China
[4] Guangdong Acad Med Sci, Dept Cardiovasc Surg, Guangdong Prov Cardiovasc Inst, Guangdong Prov Peoples Hosp, Guangzhou 510030, Peoples R China
来源
BIOSENSORS-BASEL | 2022年 / 12卷 / 08期
关键词
lung-on-a-chip; drug evaluation; EGFR; lung cancer; targeted therapy; GEFITINIB; MODELS;
D O I
10.3390/bios12080618
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
In this study, we used three-dimensional (3D) printing to prepare a template of a microfluidic chip from which a polydimethylsiloxane (PDMS)lung chip was successfully constructed. The upper and lower channels of the chip are separated by a microporous membrane. The upper channel is seeded with lung cancer cells, and the lower channel is seeded with vascular endothelial cells and continuously perfused with cell culture medium. This lung chip can simulate the microenvironment of lung tissue and realize the coculture of two kinds of cells at different levels. We used a two-dimensional (2D) well plate and a 3D lung chip to evaluate the effects of different EGFR-targeting drugs (gefitinib, afatinib, and osimertinib) on tumor cells. The 3D lung chip was superior to the 2D well plate at evaluating the effect of drugs on the NCI-H650, and the results were more consistent with existing clinical data. For primary tumor cells, 3D lung chips have more advantages because they simulate conditions that are more similar to the physiological cell microenvironment. The evaluation of EGFR-targeted drugs on lung chips is of great significance for personalized diagnosis and treatment and pharmacodynamic evaluation.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Mechanisms of resistance to EGFR-targeted drugs: lung cancer
    Morgillo, Floriana
    Della Corte, Carminia Maria
    Fasano, Morena
    Ciardiello, Fortunato
    ESMO OPEN, 2016, 1 (03)
  • [2] Evaluation of drug resistance for EGFR-TKIs in lung cancer via multicellular lung-on-a-chip
    Tan, Jianfeng
    Zhu, Leqing
    Shi, Jingyan
    Zhang, Jianhua
    Kuang, Jun
    Guo, Quanwei
    Zhu, Xiaojia
    Chen, Yuliang
    Zhou, Chengbin
    Gao, Xinghua
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 199
  • [3] EGFR-targeted anti-cancer drugs in radiotherapy:: Preclinical evaluation of mechanisms
    Baumann, Michael
    Krause, Mechthild
    Dikomey, Ekkehard
    Dittmann, Klaus
    Doerr, Wolfgang
    Kasten-Pisula, Ulla
    Rodemann, H. Peter
    RADIOTHERAPY AND ONCOLOGY, 2007, 83 (03) : 238 - 248
  • [4] Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies
    Joshi, Victoria A.
    Kucherlapati, Raju
    PHARMACOGENOMICS, 2007, 8 (09) : 1211 - 1220
  • [5] Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer
    Han, Fei
    He, Jinxi
    Li, Feng
    Yang, Jiali
    Wei, Jun
    Cho, William C.
    Liu, Xiaoming
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [6] Advanced lung organoids and lung-on-a-chip for cancer research and drug evaluation: a review
    Zhu, Leqing
    Zhang, Jianhua
    Guo, Quanwei
    Kuang, Jun
    Li, Dongfang
    Wu, Mengxi
    Mo, Yijun
    Zhang, Tao
    Gao, Xinghua
    Tan, Jianfeng
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2023, 11
  • [7] EGFR-targeted therapies in lung cancer: predictors of response and toxicity
    Heist, Rebecca Suk
    Christiani, David
    PHARMACOGENOMICS, 2009, 10 (01) : 59 - 68
  • [8] EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity
    Sandoval, Michael A.
    Sloat, Brian R.
    Lansakara-P, Dharmika S. P.
    Kumar, Amit
    Rodriguez, B. Leticia
    Kiguchi, Kaoru
    DiGiovanni, John
    Cui, Zhengrong
    JOURNAL OF CONTROLLED RELEASE, 2012, 157 (02) : 287 - 296
  • [9] EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer
    Tulchinsky, Eugene
    Demidov, Oleg
    Kriajevska, Marina
    Barlev, Nickolai A.
    Imyanitov, Evgeny
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1871 (01): : 29 - 39
  • [10] Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives
    Cheng, Xinghua
    Chen, Haiquan
    ONCOTARGETS AND THERAPY, 2014, 7 : 1689 - 1704